‘Survivor’ winner Ethan Zohn opens up about his cancer battle: I was a healthy, young guy. You never expect it to be you. – Yahoo Life

Ethan Zohn details his cancer battle to Yahoo Life. (Photo: Ethan Zohn)

Ethan Zohn is a survivor in more ways than one. The former professional soccer player rose to fame after taking home the ultimate prize on Survivor: Africa in 2001, going on to compete on the long-running reality show twice more, as well as on programs like The Amazing Race and Fear Factor. It was in 2009, however, that he faced his most personal challenge yet: a lymphoma diagnosis.

Now, Zohn who used some of his Survivor prize money to co-found Grassroot Soccer, an organization in support of HIV-AIDS prevention in Africa is an ambassador for the Lymphoma Research Foundation, the nations largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community with education programs, outreach initiatives and support services. Thus far, LRF has raised more than $67 million for the cause, which is close to Zohns heart he credits lymphoma research with saving his life following the failure of several cancer treatments.

The reality star, who returned to Survivor last year for its 20th anniversary Winners at War season, spoke to Yahoo Life about what hes learned from beating cancer and how Survivor changed the trajectory of his life.

What would you tell yourself looking back on your reality TV experience?

I would probably tell myself, "Dude, dont take everything so seriously." The whole reason I tried out for Survivor was because of a series of epic failures in my life. I was cut from my soccer team, I was unemployed, I got an advertising job in New York I was fired from. I told my mom, "Everything is okay, Ill get a job, Im just between life choices." I signed up for Survivor on a whim, and I got on. Back then, I was just a dude looking for an adventure, so when Survivor ended it was so crazy I was in the public eye, giving speeches and appearances, and it just got so overwhelming. I thought everything meant so much. Every single thing I said in a magazine. But fast forward a bunch of years, and cancer hit, and all that little stuff means nothing in the grand scheme of things. With cancer, things got pretty clear pretty quickly, so I wish I didnt spend so much time stressing out about every little thing how my hair looked. Stuff like that.

Story continues

Ethan Zohn, a three-time Survivor contestant, details his cancer battle to Yahoo Life. (Photo: Ethan Zohn)

What was your cancer diagnosis experience?

In 2008, I was working with Grassroot Soccer, which is the charity that I started using the money from Survivor to start. I did this big campaign where I dribbled a soccer ball from Boston to Washington, D.C. I started getting really itchy skin, and I tried every pill, cream and lotion known to man but it didnt help. Eventually, I was diagnosed with CD20-positive Hodgkin's lymphoma. The shock of getting that diagnosis was magnified as the only connection I had to cancer was through my dad. When I was 14, cancer came and took my dad away from me. Cancer, to me, equaled death, so when I was diagnosed, I was petrified. I was 35, I was training for the New York City Marathon. I was a healthy, young guy. You never expect it to be you. When all my friends were starting their life, I had to press pause on mine.

I went through multiple rounds of chemotherapy, 22 blasts of radiation, stem cell therapy, which worked for a little while but 20 months later the cancer returned. Getting the news that the cancer had returned was deflating, because I had already had treatment and I was running out of options. Fortunately, at that exact moment in time, just when I needed it most, there was a new targeted therapy. I was then able to then get another stem cell treatment, using my brother as a donor.

Now, Im heavily involved with the Lymphoma Research Foundation. They do an incredible amount of work for cancer research, especially blood cancer research. Personally, I wouldnt be alive if it werent for cancer research, and for organizations like the LRF. I often think to myself, How cool is it that there are complete strangers running marathons, selling cookies, donating money for a drug that helped save my life? Thats inspiring, and one of my roles as an ambassador is to show how incredible this organization is.

What is something that you wish more people knew about cancer?

Every 10 minutes, someone is diagnosed with lymphoma in the United States. To me, thats not okay, and it is a disease that affects young adults. If youre a young adult living in the United States and youre diagnosed with cancer, most likely it is going to be lymphoma. Whats been really interesting since I returned to Survivor is that Ive connected with fans over social media. Since Im so accessible now, Ive gotten many emails and DMs from fans who are like, "I saw your symptoms and because of that I went to the doctor and got diagnosed." Its been worthwhile to share my story, to work with LRF, and to help amplify that story.

Ethan Zohn is sharing details of being a lymphoma survivor. (Photo: Ethan Zohn)

What was your most meaningful reality TV experience?

Ive been on a lot of reality shows, some Im proud of and some Im not. You can guess from IMDb which ones those are. [Laughs] But on Survivor: Africa, I won a reward challenge where I received two goats. I had to take these little goats to an African village, and before I went into town I was hanging out with these kids in the parking lot of a hospital. They were touching my skin, my hair they had never seen someone who looked like me before. I took out my luxury item, a hacky sack, and we started playing. We were having an incredible time playing and laughing speaking the same language through the game of soccer. Before I left, I asked a nurse why all the kids were hanging out by the hospital? And she said, "These are the kids who are HIV positive."

Here I was, in the middle of this cutthroat game of Survivor, and I had that real-life experience. It was the first time I saw how this disease was really affecting the community. Thats when I decided to start a charity to help kids. Now, Grassroot Soccer is in 60 countries and weve graduated 13 million kids from the program all from a silly little reality show! People often look at reality TV a certain way, but if I didnt win Survivor and that money, in that moment in the center of the AIDS pandemic, who knows what would have happened.

Who would you love to compete with in your ideal game of Survivor?

I wouldnt necessarily want to compete with these people, but Id like to hang out with them on an island. Id like to play against [Portuguese soccer player] Cristiano Ronaldo. Id like to bring my dad back and play with him. And Bob Marley, because Im a huge Bob Marley fan. Ive always wanted Survivor to do a global version of Survivor. Take the winner from each country playing Survivor, and well all play against each other. I think there are 23, 24 different countries playing Survivor.

Here is the original post:
'Survivor' winner Ethan Zohn opens up about his cancer battle: I was a healthy, young guy. You never expect it to be you. - Yahoo Life

Lack of awareness about blood stem cell donation is one of the leading causes for low number of donors in In.. – ETHealthworld.com

Shahid Akhter, editor, ETHealthworld spoke to Dr. Dinesh Bhurani, Director, Department of Hemato-Oncology & Bone Marrow Transplant, Rajiv Gandhi Cancer Institute and Research Centre, to know about the progress of NPRD and the challenges associated with blood stem cell transplants.

How do you think the National Policy for Rare Diseases will impact the treatment of patients suffering from rare blood disorders? Will it help reduce the lag that we often see in policy and practice when it comes to healthcare systems? National Policy on Rare Diseases is a step-in right direction and must be welcomed by the Indian medical fraternity. It not only recognizes rare diseases for the first time in India but also has brought forward the possibility of affordable treatment for life-threatening rare diseases which were not previously covered under the national health program. The policy advocates access for treatment through center of excellences, crowd funding and financial assistance.

The NPRD in a bid to enable patients suffering from rare blood disorders has laid emphasis on the option of one-time curative treatment through hematopoietic stem cell transplant for diseases such as Severe Combined Immunodeficiency (SCID), Chronic Granulomatous disease, Wiskott Aldrich Syndrome, Osteopetrosis, and Fanconi Anaemia. By committing to provide a Rs. 20 lakhs cover for the one-time treatment cost of diseases falling under Group 1 through the umbrella scheme of Rashtriya Arogya Nidhi, the NPRD has attempted to provide coverage to almost 40 per cent of the population who are eligible under the Pradhan Mantri Jan Arogya Yojana. The NPRD as a policy that advocates affordable and accessible healthcare and has the potential to lead to the creation of a conducive healthcare ecosystem whereby multisectoral partnerships can collaboratively work towards reduction in the lag between policy and practice often seen otherwise, thereby leading people to live healthier and fuller lives.

Another reason for low number of donors in India is the misconception that stem cell donation comes with a cost to donor. This idea is completely misplaced and untrue as the cost of procedure starting from sample collection, donation and travel is free of cost, and covered under the cost of treatment of a patient for whom the donation is needed. Added to this is the fact that the number of organizations working in the country in the space of blood stem cell transplant is limited at best, thus awareness generation as compared to other health issues is nominal. However, the situation is gradually evolving and ICMR in its 2021 guidelines has gone on to recognize seven registries across the country as active stakeholders in this ecosystem. This recognition by ICMR will hopefully lead to greater awareness generation.

For blood stem cell transplant knowledge is key in establishing patient donor linkage, and by storing the requisite information with them, these registries do just that. Technology is a tool that has been successfully leveraged by stakeholders in the ecosystem to establish linkages. The Hap- E Search is one such tool that has been used by hospitals in the country to find donor matches for their patients. This software is perhaps one of the most enabling tools available to us in the ecosystem, as it helps find HLA matches not just in the country but across the world. This software is now being used by many government hospitals like AIIMS, Delhi and PGIMER Chandigarh. Once the matching donor is found via the HAP-E Search, the donor is encouraged to make the donation, provided counselling and support to donate blood stem cells, and post donation the stem cells are transported to the patients location.

The NPRD proposed crowdfunding and PPP models to ensure more patients availing treatment for rare diseases. How beneficial do you think such partnerships can be to enable blood stem cell transplant ecosystem? Treatment for rare diseases has been found to be expensive across the world. It is thus that despite stem cell transplants being a proven effective solution in the case of some blood disorders, affordability continues to be a challenge for patients and their families. With treatment costs ranging anywhere between Rs. 15-45 lakh, it remains out of reach for most patients in the country. Also, blood disorders, classified as rare, have limited infrastructure in health systems, networks, and subsidies for patients to access treatments are few. In such a scenario, crowdfunding is definitely a feasible option for patients that would ensure that they do not have to forego treatment due to a paucity of resources.

As per the NPRD, the money raised through crowdfunding would directly get credited to the treatment centre thus ensuring that there is adequate linkage. Further, the public private partnership model suggested by the government has enabled it to avail the support of non- governmental and not-for- profit agencies present in the country. This is truly commendable as not only will this ensure more patient donor linkage in the blood stem transplant ecosystem but will also lead to greater awareness generation and registrations of donors as well. One significant organization that has already partnered with the government in this arena is the DKMS BMST Foundation India. With over 50,000 blood stem cell donors registered with them, this organization has been steadily working towards enabling the ecosystem. In the case of rare diseases, it is imperative that stakeholders do not work in isolation and the government working alongside the private can lead to greater hope for many patients with greater amenities and facilities for treatment being made accessible to them.

Go here to see the original:
Lack of awareness about blood stem cell donation is one of the leading causes for low number of donors in In.. - ETHealthworld.com

The Best Skincare Treatments For Time-Crunched Moms (Or Anyone Else Who Only Has Five Minutes To Spare) – Forbes

As a beauty writer and longtime skincare fanatic, Ive subscribed to various multi-step routines. Fast forward to having a baby and the general day-to-day life upheaval that comes along with it, and my definition of a worthwhile personal beauty regimen has changed a bit. While I still enjoy trying new products and learning about innovations in the beauty space, I find myself with less time (and patience) for the more laborious treatments and layering routines, and more interest in noticeable efficacy and multitasking capabilities.

The most effective skincare products and tools are great for paring down your routineand also ... [+] saving you some precious minutes in your day.

And whether youre a busy mom or simply short on me time these days (who isnt?), there are a myriad of tried-and-true products that get the job done without requiring a ton of effort on your part. From Herauxs next-level anti-inflammaging serum to NuFaces skin-smoothing device, these standout skincare products and tools are ideal for a results-driven regimen thats effective enough to knock a few steps off your routineand save you some precious minutes in your day.

Since its launch seven years ago, this antioxidant-rich hydrating facial oil has remained a cult favorite for anyone who wants an instant glow, with the added benefit of skin soothing, balancing and repair. Infused with 22 active botanical and essential oils, the lightweight yet potent treatment can help with everything from acne to sun damage. And when applied using founder April Gargiulos signature push-press technique, it feels like a simple yet luxurious way to start and end the day.

Like the brands Trinity device, the NuFace Fix uses microcurrent technology at a gentler level to help reduce the look of fine lines and wrinkles on the more delicate areas of the face: on the forehead, between brows and around the eyes and lips (filler-free plumping, anyone?). Its sleek, compact shape combined with ease of use makes it a no-brainer for skin smoothing results in a matter of minutes. Plus, it holds an ample 120-minute charge, which amounts to a couple months worth of use before needing to plug it ini.e. no fumbling with cords or a hefty device on a regular basis.

The latest product in Kate McLeods sustainably packaged, handcrafted self care collection and the first to focus on skincare, the Face Stone is essentially a waterless moisturizer that melts on contact with skin. A rich blend of nourishing and antioxidant ingredients like blue tansy, kokum butter and plum kernal borage helps even and soothe stressed skinsomething we could all use these days. An added bonus? Its solid form and shape makes it a natural massaging tool, making it ideal for a morning pick-me-up or the start of an evening wind-down ritual.

While it covers your mineral-based broad spectrum sunscreen needs, this multitasker does much more than that. The unique product uses the U Beautys proprietary Sun-Siren Capsule Technology to help reduce hyperpigmentation, discoloration and dark spots (whether from pregnancy melasma or suntanning sins of the past) while also shielding against UVA, UVB, infrared and blue light exposure. A little goes a long way with this rich balm-cream formula, and its hydrating enough to double as a moisturizer or primer by day and also great as an overnight spot treatment.

An excellent (and cleaner) dupe for Biologique Recherches oft-elusive Lotion P50, this Moon Juice exfoliator is a skin savior in its own right. The liquid formula includes glycolic, lactic and salicylic acids for gentle, pore-minimizing exfoliation paired with niacinamide and adaptogenic reishi to help boost the skins natural barrier. And besides looking pretty, the packaging is completely recyclable, from the sculptural cap and glass bottle to the outer carton.

January Labs is a clean beauty favorite for its science-backed, results-driven products that have long been favored by top aestheticians. Even those with more sensitive (or dry) skin can use this retinol serum without dealing with typical downsides (like redness, drying or peeling) thanks to its use of Retistar, a .5% retinol thats super effective yet non-irritating.

This at-home peel is as easy as can be, requiring a single once-over with the pre-soaked pad to revive dull skin. The duo of glycolic and salicylic acids provide skin-smoothing exfoliation while ingredients like chamomile and bilberry extract calm, soothe and help even skin tone. Pro tip: Use up excess product on any dry, flakey patches on arms and legs.

Created by stem cell biologists at the University of Southern California, this innovative serum features an anti-inflammaging HX-1 molecule thats combined with tried-and-tested ingredients like vitamin C, hyaluronic acid, peptides and red maple bark. The result? A silky, lightweight formula thats both rejuvenating (designed to help reduce the effects of stress and aging factors on skin) and preventative (strengthening stem cells on a molecular level).

Go here to see the original:
The Best Skincare Treatments For Time-Crunched Moms (Or Anyone Else Who Only Has Five Minutes To Spare) - Forbes

[PDF] Stem Cell Therapy Market Size Strong Revenue and Generated Opportunities UNLV The Rebel Yell – UNLV The Rebel Yell

Stem cells are divided into two major classes; pluripotent and multipotent. Pluripotent stem cells are replicating cells, which are derived from the embryo or fetal tissues. The pluripotent stem cells facilitate the development of cells and tissues in three primary germ layers such as mesoderm, ectoderm, and endoderm.

Increasing expansion of facilities by market players for stem cell therapies is expected to propel growth of the stem cell therapy market over the forecast period. For instance, in January 2018, the University of Florida, U.S. launched the Center for Regenerative Medicine that is focused on development of stem cell therapies for the treatment of damaged tissue and organ. The Centre for Regenerative Medicines is divided into two segments such as focus groups and shared services. Focus groups such as research and development activities for stem cell therapies; and the shared services segment offers technical resources related to stem cell therapies.

FREE | Request Sample is Available @https://www.coherentmarketinsights.com/insight/request-sample/2848

*The Sample only consist ofTable of Content (ToC).Research Frameworkof the actual report. Research Methodologyadopted for it.

Furthermore, rising collaboration activities by key players are expected to drive growth of the global stem cell therapy market. For instance, in May 2018, Procella Therapeutics and Smartwise, a medtech company entered into a collaboration with AstraZeneca Pharmaceuticals. Under this collaboration, AstraZeneca utilized Procella Therapeutics stem cell technology for the development of stem cell therapies in cardiovascular diseases. Moreover, in April, 2019, CelluGen Biotech and FamiCord Group collaborated to develop new stem cell-based drugs and advanced medical therapies (ATMP)

Major Company Profiles Covered in This Report:Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Anterogen Co. Ltd., Pharmicell Co., Inc., and Stemedica Cell Technologies, Inc.

Download Free PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2848

Increasing research and development activities by the market players are one of the major factors that are expected to drive growth of the stem cell therapy market over the forecast period. For instance, in July 2018, the Emory Orthopaedics & Spine Center, in collaboration withSanford Health, Duke University, Andrews Institute, and Georgia Institute of Technology, received US$ 13 million grant from the Marcus Foundationfor a multicenter clinical trial studying stem cell options for treating osteoarthritis.The Phase 3 trial was initiated in March 2019, and is expected to complete by December 2021. Moreover, in December 2017, Mayo Clinic initiated the clinical phase I study on safety and feasibility of mesenchymal stem cell therapy in patients with intracerebral hemorrhage. This therapy is used for treating acute spontaneous hemorrhagic stroke. The study is expected to complete by December 2020.

Moreover, increasing product launches by key players is expected to boost demand for stem cell therapy over the forecast period. For instance, in August 2017, LifeCell, a healthcare service provider, launched an advanced umbilical cord-stem cell collection kit which offers enhanced protection to neonatal stem cells from environmental damage and temperature fluctuations.

Inquire more about this report @https://www.coherentmarketinsights.com/insight/talk-to-analyst/2848

Frequently Asked Questions

What are the key factors driving Stem Cell Therapy Market expansion?

What will be the value of Stem Cell Therapy Market during 2020- 2027?

Which region will make notable contributions towards global Stem Cell Therapy Market revenue?

What are the key players leveraging Stem Cell Therapy Market growth?

Also, Research Report Examines:

Competitive companies and manufacturers in global market

By Product Type, Applications & Growth Factors

Industry Status and Outlook for Major Applications / End Users / Usage Area

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

See original here:
[PDF] Stem Cell Therapy Market Size Strong Revenue and Generated Opportunities UNLV The Rebel Yell - UNLV The Rebel Yell

Mike Tysons weird stem cell treatment has helped transform incredible body at 55 – Daily Star

Mike Tyson has claimed that he underwent stem-cell treatment several years ago, which transformed his body but left him feeling weird ever since".

Former heavyweight champion Tyson was one of the most physically intimidating boxers of all-time, boasting tremendous speed and devastating power throughout his career.

However, following his retirement from boxing in 2005, Tyson moved away from the sport entirely and began to gain weight.

This all changed several years ago, when Tyson made the decision to turn his life around and get back into fighting shape.

Alongside changing his diet and daily routine, Tyson recently stated that he underwent stem-cell therapy to aid his body transformation.

In recently resurfaced footage of an interview with LL Cool J on SiriusXM last year, via The Sun, Tyson told the rapper about undergoing the therapy, which aims to repair damaged cells within the body and treat or prevent illness.

"Yes. As they took the blood it was red and when it came back it was almost transfluid (sic), Tyson claimed.

"I could almost see through the blood, and then they injected it in me.

"And Ive been weird ever since, Ive got to get balanced now."

Who do you want to see Mike Tyson fight next? Let us know in the comments section below.

Since undergoing his incredible body transformation, Tyson has returned to boxing with incredible results.

He recently competed for the first time in over a decade-and-a-half in an exhibition bout against fellow legend Roy Jones Jr. While Jones looked out of shape, Tyson looked in peak condition.

While the bout was deemed a draw, Tyson won the bout in most viewers eyes and impressed throughout the contest.

After the pay-per-view success of his bout with Jones Jr, Iron Mike is expected to return to the ring again, either later this year or early next year.

An opponent has not yet been announced, however, Tyson has been training intensely with coach Rafael Cordeiro and looks ready for another fight very soon.

Get your hands on your club's special edition 2021/22 annual. Find out more here.

Visit link:
Mike Tysons weird stem cell treatment has helped transform incredible body at 55 - Daily Star

Acute Monocytic Leukemia: Causes, Symptoms, and Treatment – Healthline

Leukemia is a group of cancers that affect your bone marrow and cause your body to produce abnormal blood cells. Acute myeloid leukemia (AML) is the most common type of leukemia in adults and accounts for about 4 out of 5 adult cases.

Acute monocytic leukemia (AML-M5) is a subtype of AML, in which at least 80 percent of the affected blood cells are a type of white blood cell called monocytes. Half of the people diagnosed with AML M5 are older than age 49.

AML-M5 causes similar symptoms in the early stages as other types of leukemia. These symptoms include:

In this article, we take a look at how acute monocytic leukemia differs from other leukemias, how its treated, and whats the outlook.

Leukemias develop in bone marrow stem cells that produce blood cells. Theyre classified based on the type of blood cells affected and how quickly the disease progresses. Heres how each main type is broken down:

AML is a type of leukemia that develops quickly (acute) and affects myeloid cells (myeloid).

AML-M5 is a subtype of AML that mainly affects the growth of monocytes. Monocytes have the potential to become two other types of white blood cells called macrophages and dendritic cells.

According to the National Cancer Institute, AML-M5 is diagnosed when more than 20 percent of white blood cells are abnormal or not fully developed, and more than 80 percent of the abnormal cells are monocytes or cells derived from monocytes.

Like many types of cancer, its not entirely clear why AML-M5 develops in some people and not others. However, it has been linked to certain genetic mutations.

In a 2019 study, genetic mutations were detected in 83.3 percent of people with AML-M5. The mutations FLT3-ITD and NRAS were most common.

Symptoms of AML-M5 are similar to those of many other forms of leukemia. Symptoms like fatigue or feelings of weakness are general and can have many potential causes.

Some other possible symptoms of AML-M5 include:

Many of the symptoms of leukemia are general and can have many different causes. A healthcare professional will likely want to order a blood test to look for signs of the disease, such as a high number of abnormal white blood cells or a low blood count.

If your blood test reveals signs of leukemia, youll likely be referred to a doctor called a hematologist, who specializes in blood conditions.

The next part of your diagnosis will likely involve a bone marrow biopsy, usually from your hip bone. During this procedure, an anesthetic will be applied to your skin. Then, the doctor will use a thin needle to remove bone marrow from the center of your hip bone.

The procedure usually takes about 20 to 30 minutes and shouldnt be painful. Your sample will then be taken to a lab for analysis.

Other supportive tests may be used to collect more information about the specific type of AML you have, how far it has progressed, and what the best treatment option may be.

AML-M5 can be difficult to treat due to a limited amount of research on the best way to manage this specific type of AML.

Treatment for most forms of AML involves multidrug chemotherapy and bone marrow transplants. The amount of chemotherapy you can receive depends on factors such as your age and overall health.

The goal of induction chemotherapy is to kill as many cancer cells as possible. It involves taking a high dose of chemotherapy drugs that target cancer cells. Unfortunately, it also targets healthy cells in your body that divide rapidly, such as blood stem cells, skin cells, and gastrointestinal cells.

The strength of the chemotherapy you can handle may depend on your age or overall health. Chemotherapy drugs are highly toxic to your bone marrow and can cause bleeding complications, kidney failure, and other potentially serious side effects, so your doctor will run tests often to check your health.

The chemotherapy drug cytarabine and either daunorubicin or idarubicin are often used in a 7+3 regimen. This mean you get cytarabine through an IV for 7 days, along with a small dose of one of the other medications on the first 3 days.

Here are a few other variations in the way this treatment might work:

Typically, youll stay in the hospital during the induction phase. If there are still signs of cancer in your body at the end of treatment, you may need another round of chemotherapy.

After going into remission, meaning the cancer is no longer detectable, most people undergo additional chemotherapy to target any remaining undetectable cancer cells and keep the cancer from coming back.

Young and healthy individuals often undergo several cycles of high-dose cytarabine combined with bone marrow transplants. Older adults or those with other coexisting health conditions may receive lower doses of cytarabine or other chemotherapy drugs.

High doses of chemotherapy damage the cells in your bone marrow that produce blood cells. A bone marrow transplant replaces damaged cells with healthy ones. Two types of transplants may be performed:

When a suitable donor is available, allogeneic transplants are the preferred procedure.

The outlook for people with AML-M5 has not been clearly established. However, it is known that it often progresses quickly when left untreated.

When your body makes too much of a protein called differentiation inhibitory factor, it may be linked to a less promising prognosis in some people.

About 40 percent of people with AML-M5 have a mutation in their Flt3 gene, which also may be associated with a less favorable outcome.

In a 2020 study, researchers found the 5-year overall survival rate was 46 percent in a group of 132 children with AML-M5. The overall survival rate was lowest in children under 3 years old.

Researchers are continuing to study AML-M5 in clinical trials to find the best way to treat this type of leukemia. Its likely the survival rate will continue to improve with time and new data.

Many types of leukemia that used to have high mortality rates are now very treatable, thanks to medical advancements. You can ask your doctor about clinical trials in your area, or you can search for them yourself from the U.S. National Library of Medicine.

Originally posted here:
Acute Monocytic Leukemia: Causes, Symptoms, and Treatment - Healthline

UC Davis and the School of Medicine set new records in research funding – UC Davis Health

The University of California, Davis, set a new record for external research funding, receiving $968 million in awards in the fiscal year 2020-21, up $27 million from the previous record set last year. A major reason for this years growth was increased funding related to medicine and public health.

Professors Diana Farmer and Aijun Wang are collaborating to develop a stem cell treatment for spina bifida. (2019)

The School of Medicine received the largest increase in funding, up $92 million from the previous year, for a total of $368 million. Funding related to COVID-19 research totaled $42 million for the year. Studies in this area are providing critical insight into testing, vaccines, treatments and social impacts.

We are very proud of our researchers at the School of Medicine who rose to the challenge and expanded their groundbreaking work in the face of the pandemic, said Allison Brashear, dean of the UC Davis School of Medicine. All our research teams have shown great agility and collaboration across disciplines, quickly responding to emerging needs to prevent transmission and find treatments and vaccines to combat COVID-19, while also offering patients life-saving clinical trials in areas involving stem cell treatments, cancer and neuroscience, among many others.

Brashear noted that the School of Medicines clinical trials grew by 63% in the last year to $98 million.

The College of Agricultural and Environmental Sciences ($153 million), School of Veterinary Medicine ($83 million), College of Engineering ($80 million) and College of Biological Sciences ($58 million) rounded out the top five recipients.

This achievement reflects the unwavering commitment of our research community and their passion to address important societal needs during a year when operations were constrained due to the COVID-19 pandemic, Chancellor Gary S. May said. The societal impact of UC Davis research is far-reaching, spanning geographical boundaries and catering to diverse populations and needs.

The awards enable a broad range of research on topics including advancing human and animal health, protecting our planet and food supply and enabling a more resilient society.

The largest award, $51 million from the Department of Health and Human Services Centers for Disease Control and Prevention, went to Marc Schenker, distinguished professor of Public Health Sciences, to improve public health outcomes for all Californians by providing proper disease surveillance and prevention.

The federal government remains the largest provider of funding at $514 million, up $37 million from last year. The second leading source came from the state of California at $164 million, up $32 million. Funding from industry made up the third highest source, totaling $116 million, up $31 million.

UC Davis researchers received a total of 18 NSF CAREER Awards, a record for the university. These prestigious grants are offered to early-career faculty who have the potential to serve as academic role models in research and education and to lead advances in the mission of their department or organization.

Collaborative research bringing experts together from different fields of study continues to attract significant funding. These joint efforts often focus on addressing complex, large-scale challenges that require expertise from many perspectives.

We continue to see how multidisciplinary research provides a distinct advantage in tackling multifaceted issues, said Prasant Mohapatra, vice chancellor for Research at UC Davis. As one of the most academically comprehensive universities in the world, UC Davis offers a unique environment to solve these complex issues by bringing together experts from across our campuses.

Notable multidisciplinary awards include a $16 million grant from the National Institute of Mental Health for the UC Davis Conte Center to explore how infections in pregnancy lead to disorders in offspring. Principal investigators on this grant are Kimberly McAllister and Cameron Carter.

The Interdisciplinary Research and Strategic Initiatives division within the Office of Research offers support and resources to help teams advance their programs. Some of the notable interdisciplinary research projects include the work of Sheryl Catz, professor at the UC Davis Betty Irene Moore School of Nursing. Catz received $225,000 from the NIH National Cancer Institute for a project to improve the reach and effectiveness of smoking cessation services targeted to veterans living with HIV.

Diana Farmer, professor and chair in the Department of Surgery at UC Davis Health, also received $9 million from the California Institute for Regenerative Medicine (CIRM). Farmer is the principal investigator of the clinical trial, known formally as The CuRe Trial a cellular therapyfor in utero repair of myelomeningocele which uses stem cells before birth to treat the most serious form of spina bifida.

This story was originally written by Neelanjana Gautam and published here.

Note: Where funds are awarded up-front to cover several years, the money is counted in the first year the award was received. Incrementally funded awards are counted as authorized in each year. Reports are based on the principal investigators home school or college.

See the article here:
UC Davis and the School of Medicine set new records in research funding - UC Davis Health

DHEC Supports Awareness and Education during National Sickle Cell Awareness Month – SCDHEC

FOR IMMEDIATE RELEASE: Aug. 30, 2021

COLUMBIA, S.C. Sickle cell disease is a serious genetic disorder that impacts many families around the country and around the world. The South Carolina Department of Health and Environmental Control (DHEC) supports the annual recognition of September as National Sickle Cell Awareness Month to help focus attention on the need for further research and treatment of sickle cell disease.

As the most common inherited blood disorder in the United States, sickle cell disease (SCD) currently affects approximately 100,000 Americans, including more than 4,000 South Carolinians who have the disease. Complications from SCD include pain attacks that can cause the individual to need hospitalization. Other potentially life-threatening complications include infections, stroke, and organ damage.

Because symptoms and complications of SCD can vary, treatment options are different for each person depending on their symptoms. The only known cure for SCD is bone marrow or stem cell transplant.

Sickle cell disease can be a debilitating and life-threatening disease for those who have it, and it can also affect the lives of their family and friends, said Dr. Brannon Traxler, DHEC Public Health Director. While September is National Sickle Cell Awareness Month, increasing public knowledge about sickle cell should be a year-long initiative.

The theme of this years monthly recognition is Sickle Cell Matters, which underscores the need to raise awareness about the daily struggles of those living with SCD as well as the need to address the stereotypes and stigmas associated with people who have the disorder.

Babies are born with SCD; it isnt a disease that someone can develop later in life. In people who are born with SCD, both copies of a hemoglobin gene are abnormal. A person born with one abnormal copy of the gene and one normal copy has "sickle cell trait." People with sickle cell trait usually don't have symptoms although in rare cases they can experience complications of SCD like pain crises. When two people with sickle cell trait have a child, there is a 25-percent chance the child will have SCD. Even if only one parent has a sickle cell trait, their child could still have an increased risk of inheriting a type of sickle cell disease.

Blood tests can confirm whether a person has sickle cell trait or SCD, and the disorders are commonly detected during newborn health screenings.

SCD disproportionally affects those with African ancestry or who identify as Black. The disease also can be found in anyone with genetic makeup from a part of the world where malaria is more widely spread, such as India, South America and Central America.

South Carolina has a Sickle Cell Disease State Plan developed by a group of dedicated partners who work to help mitigate this life-threatening disorder, said Dr. Traxler. We can all help increase awareness about sickle cell disease by sharing education and information within our communities, especially in minority or underserved communities that may struggle with access to routine health care.

In 2017, South Carolina established the South Carolina Sickle Cell Disease Advocacy Team, which remains focused on one common goal to improve the treatment and care received by individuals and their families who have sickle cell disease.

DHEC provides a printable sickle cell disease flyer available for anyone here. Organizations can order printed copies of the flyer for distribution by placing an order here. Learn more about the disease at cdc.gov/sicklecell.

###

About the South Carolina Sickle Disease Advocacy Team Members of the South Carolina Sickle Cell Disease Advocacy Team (SCSCDAT), who came together to develop the South Carolina Sickle Cell Disease State Plan, include physicians, hematologists, government agencies non-profit organizations, healthcare management organizations and individuals living with SCD and their family members.

Media Contacts:

COBRA Sickle Cell Program http://www.cobraagency70.com/home.html sicklecell@cobraagency70.com 843-225-4870

Louvenia D. Barksdale Sickle Cell Anemia Foundation http://www.ldbarksdalesc.org/ ldbarksdalesc@gmail.com 864-582-9420

James R Clark Memorial Sickle Cell Foundation http://www.jamesrclarksicklecell.org office@jamesrclarksicklecell.org 803-799-6471

Orangeburg Area Sickle Cell Anemia Foundation orangeburgsickle@gmail.com 803-534-1716

The B Strong Group thebstronggroup.org thebstronggroup@gmail.com 803-875-1266

DRE 365 (Dream Reach Empower) dre365sc@gmail.com 803-759-0700

Here is the original post:
DHEC Supports Awareness and Education during National Sickle Cell Awareness Month - SCDHEC

NCCN Issues Updated Guidelines Regarding Third COVID-19 Vaccine Booster for Those With Cancer – Cancer Network

The National Comprehensive Cancer Network (NCCN) has announced a significant update to the guidelines for COVID-19 vaccine administration, including a third dose, in patients with cancer, according to a press release issued by the organization.1

The recommendation indicated that several groups of individuals should be eligible for a third dose of the COVID-19 vaccine, including those with new or recurring solid tumors within 1 year of their initial vaccine dose regardless of therapy, as well as those with active hematologic malignancies. Patients who have received a stem cell transplant (SCT) or engineered cellular therapy such as CAR T-cell therapy within the past 2 years should also eligible, as well as those who are recipients of SCT on immunosuppressive therapy or with a history of graft-versus-host disease regardless of when the transplant took place.

COVID-19 can be very dangerous, especially for people living with cancer, which is why were so grateful for safe and effective vaccines that are saving lives, Robert W. Carlson, MD, chief executive officer of the NCCN, said in a press release. Our organization exists to improve the lives of people with cancer; we have a long track record for making recommendations that improve quality and length of life. We want our patients to live the longest and best lives possible, which means following the science on vaccination and mask-wearing.

The NCCN COVID-19 Vaccine Advisory Committee consists of multidisciplinary physicians across the NCCNs Member Institutions. In particular, the committee includes experts in infectious diseases, vaccine development and delivery, cancer management, and medical ethics. The recommendations, which are based on available evidence and expert consensus, have been utilized globally to aid in making management decisions over the course of the COVID-19 pandemic.

When it comes to peoples safety, we have to take every precaution, Steve Pergam, MD,

MPH, associate professor of the Vaccine and Infectious Disease Division at Fred Hutchinson

Cancer Research Center and infection prevention director at Seattle Cancer Care Alliance, as well as the co-leader of the NCCN COVID-19 Vaccination Advisory Committee, said in a press release. That means even after a third dose of vaccine, we still recommend immunocompromised peoplesuch as those undergoing cancer treatmentcontinue to be cautious, wear masks, and avoid large group gatherings, particularly around those who are unvaccinated. All of us should do our part to reduce the spread of COVID-19 and get vaccinated to protect those around us from preventable suffering.

Additional recommendations from the updated guidelines suggest that all eligible caregivers and close contacts of those with cancer should be immunized whenever possible.2 The use of all vaccines with FDA approval or emergency use authorizationincluding the Pfizer/BioNTech BNT162b2 mRNA vaccine (Comirnaty), the Moderna mRNA-1273 SARS-CoV-2 vaccine, and the Janssen Ad26.COV2.S Adenovirus vector vaccineis recommended in eligible patients by the committee.

Those who are receiving allogeneic or autologous SCT or CAR T-cell therapy will need to wait at least 3 months post-therapy before receiving the vaccine. Patients with hematologic malignancies, including those receiving cytotoxic chemotherapy such as cytarabine and anthracycline-based induction regimens for acute myeloid leukemia, need to delay inoculation until absolute neutrophil count recovery. Those who are experiencing marrow failure from their disease and/or are expected to have limited or no recovery from their therapy as well as those who are receiving long-term maintenance are able to receive the vaccine once it is available.

In solid tumors, the vaccine may be received once available for those who are undergoing treatment with cytotoxic chemotherapy, targeted therapy, checkpoint inhibitors, and other immunotherapy or radiation therapy. Those who are undergoing major surgery need to wait a few days following their surgical procedure before getting the vaccines.

The Center for Disease Control (CDC) currently recommends a third dose of the mRNA COVID-19 vaccines for individuals who are moderately to severely immunocompromised. This includes:

The CDC recommends that a third dose of the mRNA COVID-19 vaccine should be given at a minimum of 4 weeks following the second dose of either the Moderna or Pfizer vaccines. Notably, although preliminary data indicate that a third dose could augment antibody titers in an immunocompromised population of patients, those who have been diagnosed with cancer continue to be at a higher risk for infection with COVID-19 and COVID-19related complications. Even with the additional dose, infection is still possible meaning that precautions such as avoiding crowds and wearing a mask are recommended.

More here:
NCCN Issues Updated Guidelines Regarding Third COVID-19 Vaccine Booster for Those With Cancer - Cancer Network

Global Cryopreservation Equipment Market Report 2021-2028 – Growing Acceptance for Regenerative Medicine & Increasing Needs of Biobanking…

DUBLIN--(BUSINESS WIRE)--The "Cryopreservation Equipment Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Type, Cryogen Type, Application, End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

Freezers Segment to Contribute Major Share to Cryopreservation Equipment Market

Cryopreservation Equipment Market to reach US$ 11,255.02 million by 2028 from US$ 5,798.82 million in 2021; it is estimated to grow at a CAGR of 9.9%

The report highlights the trends prevailing in the market along with the market drivers and deterrents. The factors such as growing acceptance for regenerative medicine and increasing needs of biobanking practices drive the market growth. However, stringent regulatory requirements hinder the cryopreservation equipment market growth.

Cryopreservation plays an important part in the field of regenerative medicine as it facilitates stable and secure storage of cells and other related components for a prolonged time. Regenerative medicine enables replacing diseased or damaged cells, tissues, and organs by retrieving their normal function through stem cell therapy.

Owing to the advancements in the medical technology, stem cell therapy is now being considered as an alternative to traditional drug therapies in the treatment of a wide range of chronic diseases, including diabetes and neurodegenerative diseases.

Moreover, the US Food and Drug Administration (FDA) has approved blood-forming stem cells. The blood-forming stem cells are also known as hematopoietic progenitor cells that are derived from umbilical cord blood. The growing approvals for stem cell and gene therapies are eventually leading to the high demand for cryopreservation equipment. Following are a few instances of stem cell and gene therapies approved by the FDA and other regulatory bodies.

Based on type, the cryopreservation equipment market is segmented into freezers, sample preparation systems, and accessories. In 2020, the freezers segment held the largest share of the market, and it is expected to register the highest CAGR during 2021-2028. In ultracold freezers, liquid nitrogen is used for the successful preservation of more complex biological structures by virtually seizing all biological activities.

The COVID-19 pandemic has had a mixed impact on the cryopreservation equipment market. Restricted access to family planning services as well as diverted focus of people due to economic uncertainties and recession, and disturbed work-life balance have led to rise in egg and embryo freezing activities at fertility clinics during the pandemic.

As a result, the rising use of cryopreservation equipment is boosting the market growth. Furthermore, supply chain disruption caused due to congestion of ports and disturbances in other transport means has substantially affected the distribution of cryopreservation equipment and other accessories.

Market players are launching new and innovative products and services to maintain their position in the cryopreservation equipment market. In May 2021, Stirling Ultracold has been acquired by BioLife Solutions, Inc for cell and gene therapies and the broader biopharma market. In return for all of Stirling's outstanding shares, BioLife issued 6,646,870 shares of ordinary stock.

Key Market Dynamics

Market Drivers

Market Restraints

Market Opportunities

Future Trends

The report segments the global cryopreservation equipment market as follows:

By Type

By Cryogen Type

By Application

By End User

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/tjgti5

Visit link:
Global Cryopreservation Equipment Market Report 2021-2028 - Growing Acceptance for Regenerative Medicine & Increasing Needs of Biobanking...